Pink Sheet reporters and editors discuss questions about Sarepta’s Duchenne muscular dystrophy gene therapy candidate (0:32), the US FDA’s efforts to simplify the COVID-19 vaccine schedule (13:15), and industry’s ideas for Medicare price negotiation system changes (24:18).
Read More In The Pink Sheet
CBER Director Marks’ Intervention On Sarepta Gene Therapy Filing Decision Appears To Backfire: https://pink.pharmaintelligence.informa.com/PS148055/CBER-Director-Marks-Intervention-On-Sarepta-Gene-Therapy-Filing-Decision-Appears-To-Backfire
If New COVID-19 Vaccine Recommendations Land In the United States, Do They Make Sound? https://pink.pharmaintelligence.informa.com/PS148080/If-New-COVID19-Vaccine-Recommendations-Land-In-the-United-States-Do-They-Make-Sound
PhRMA’s Opening Gambit: Limiting Medicare Price Setting To The IRA's Minimum Discount: https://pink.pharmaintelligence.informa.com/PS148072/PhRMAs-Opening-Gambit-Limiting-Medicare-Price-Setting-To-The-IRAs-Minimum-Discount
Podden och tillhörande omslagsbild på den här sidan tillhör Citeline. Innehållet i podden är skapat av Citeline och inte av, eller tillsammans med, Poddtoppen.
